Likewise, Morinobu et al. [28] found no significant difference in the rate of improvement in treatment and the severity of side effects between patients with and without the CYP2C19*2 (m1) and *3 (m2) polymorphisms in a group of Japanese MDD patients treated with imipramine. Here, CYP2C19 is linked to major depressive disorder.